TCS 3,545.00 -5.35 (-0.15%) HDFCBANK 1,797.40 +30.10 (1.70%) 
HINDUNILVR 2,242.00 +8.35 (0.37%) INFY 1,549.85 +22.35 (1.46%) HDFC 2,729.95 -17.05 (-0.62%) BHARTIARTL 1,754.75 +30.85 (1.79%) KOTAKBANK 2,153.00 +7.75 (0.36%) ICICIBANK 1,330.75 +13.15 (1.00%) ITC 408.95 +2.30 (0.57%) BAJFINANCE 8,667.95 -28.95 (-0.33%) MARUTI 11,715.05 +239.50 (2.09%) HCLTECH 1,531.85 +2.40 (0.16%) SBIN 775.85 +4.35 (0.56%) NESTLEIND 2,201.85 -30.25 (-1.36%) ASIANPAINT 2,306.65 -8.75 (-0.38%) WIPRO 263.65 +1.00 (0.38%) DMART 4,116.30 +112.15 (2.80%) AXISBANK 1,084.85 -0.50 (-0.05%) LT 3,421.65 -14.20 (-0.41%) HDFCLIFE 695.70 +2.60 (0.38%) SUNPHARMA 1,714.25 +17.30 (1.02%) ULTRACEMCO 11,276.35 -100.00 (-0.88%) ONGC 250.45 +2.30 (0.93%) BAJAJFINSV 1,923.25 -13.25 (-0.68%) BPCL 286.85 +2.05 (0.72%) POWERGRID 286.70 -2.55 (-0.88%) TITAN 3,099.05 +112.55 (3.77%) BRITANNIA 5,048.30 +148.60 (3.03%) NTPC 351.90 -0.25 (-0.07%) Download Unicorn Signals App
By EquityPandit
On Monday, Punjab based IOL Chemicals and Pharmaceuticals said that it has got approval from the US health regulator USFDA for its Ibuprofen manufacturing facility in Barnala, Punjab.
In a BSE filing, IOLCP said, the company has received establishment inspection report from the US Food and Drug Administration (USFDA) for the Barnala-based facility.
“Post this approval, IOLCP will be able to garner additional business for its flagship Iburofen in world’s largest pharma market–USA,” it added.
